Designing hypoallergenic derivatives for allergy treatment by means of in silico mutation and screening

Journal of Allergy and Clinical Immunology

Volumn 125, Issue 4, 2010, Pages

  Thalhamer, Theresa ^a   Dobias, Heidi ^b   Stepanoska, Tatjana ^a   Pröll, Martina ^a   Stutz, Hanno ^a   Dissertori, Oliver ^a   Lackner, Peter ^a   Ferreira, Fatima ^a   Wallner, Michael ^a   Thalhamer, Josef ^a   Hartl, Arnulf ^b  

^a UNIVERSITY OF SALZBURG   (Austria)

^b PARACELSUS MEDICAL UNIVERSITY   (Austria)

Author keywords

Bet v 1; DNA vaccines; hypoallergen; in silico mutation; knowledge based potential; Phl p 5; recombinant allergen; Specific immunotherapy; type I allergy; z score

Indexed keywords

BLOCKING ANTIBODY; EPITOPE; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; MUTANT PROTEIN; RBET MUT 123 PROTEIN; RBET MUT 1234 PROTEIN; RECOMBINANT ALLERGEN; RECOMBINANT BET V 1A; RECOMBINANT PHL P 5B; UNCLASSIFIED DRUG;

ALLERGENICITY; ALLERGY; AMINO ACID SEQUENCE; ANIMAL CELL; ANTIGEN BINDING; ANTIGENICITY; ARTICLE; BASOPHIL; BIOASSAY; BIOCHEMISTRY; BIRCH; CALCULATION; CELLULAR IMMUNITY; COMPUTER MODEL; CROSS LINKING; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOGENICITY; IMMUNOLOGY; MOUSE; MUTAGENESIS; NONHUMAN; POINT MUTATION; POLLEN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; SCREENING; T LYMPHOCYTE;

EID: 77950205047     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2010.01.031     Document Type: Article

References (44)

1. Wills-Karp M., Santeliz J., and Karp C.L. The germless theory of allergic disease: revisiting the hygiene hypothesis. Nat Rev Immunol 1 (2001) 69-75
2. Larche M., Akdis C.A., and Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol 6 (2006) 761-771
3. Bousquet J., Lockey R., Malling H.J., Alvarez-Cuesta E., Canonica G.W., Chapman M.D., et al. Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. American academy of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 81 (1998) 401-405
4. Valenta R. The future of antigen-specific immunotherapy of allergy. Nat Rev Immunol 2 (2002) 446-453
5. Ball T., Sperr W.R., Valent P., Lidholm J., Spitzauer S., Ebner C., et al. Induction of antibody responses to new B cell epitopes indicates vaccination character of allergen immunotherapy. Eur J Immunol 29 (1999) 2026-2036
6. Moverare R., Elfman L., Vesterinen E., Metso T., and Haahtela T. Development of new IgE specificities to allergenic components in birch pollen extract during specific immunotherapy studied with immunoblotting and Pharmacia CAP System. Allergy 57 (2002) 423-430
7. Ferreira F., Wallner M., and Thalhamer J. Customized antigens for desensitizing allergic patients. Adv Immunol 84 (2004) 79-129
8. Jutel M., Jaeger L., Suck R., Meyer H., Fiebig H., and Cromwell O. Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol 116 (2005) 608-613
9. Ball T., Linhart B., Sonneck K., Blatt K., Herrmann H., Valent P., et al. Reducing allergenicity by altering allergen fold: a mosaic protein of Phl p 1 for allergy vaccination. Allergy 64 (2009) 569-580
10. van Hage-Hamsten M., Kronqvist M., Zetterstrom O., Johansson E., Niederberger V., Vrtala S., et al. Skin test evaluation of genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1: results obtained with a mix of two recombinant Bet v 1 fragments and recombinant Bet v 1 trimer in a Swedish population before the birch pollen season. J Allergy Clin Immunol 104 (1999) 969-977
11. Ferreira F., Ebner C., Kramer B., Casari G., Briza P., Kungl A.J., et al. Modulation of IgE reactivity of allergens by site-directed mutagenesis: potential use of hypoallergenic variants for immunotherapy. FASEB J 12 (1998) 231-242
12. Wagner S., Radauer C., Bublin M., Hoffmann-Sommergruber K., Kopp T., Greisenegger E.K., et al. Naturally occurring hypoallergenic Bet v 1 isoforms fail to induce IgE responses in individuals with birch pollen allergy. J Allergy Clin Immunol 121 (2008) 246-252
13. Wallner M., Stocklinger A., Thalhamer T., Bohle B., Vogel L., Briza P., et al. Allergy multivaccines created by DNA shuffling of tree pollen allergens. J Allergy Clin Immunol 120 (2007) 374-380
14. Sippl M.J. Recognition of errors in three-dimensional structures of proteins. Proteins 17 (1993) 355-362
15. Wiederstein M., and Sippl M.J. Protein sequence randomization: efficient estimation of protein stability using knowledge-based potentials. J Mol Biol 345 (2005) 1199-1212
16. Sheffield P., Garrard S., and Derewenda Z. Overcoming expression and purification problems of RhoGDI using a family of "parallel" expression vectors. Protein Expr Purif 15 (1999) 34-39
17. Hartl A., Weiss R., Hochreiter R., Scheiblhofer S., and Thalhamer J. DNA vaccines for allergy treatment. Methods 32 (2004) 328-339
18. Hochreiter R., Stepanoska T., Ferreira F., Valenta R., Vrtala S., Thalhamer J., et al. Prevention of allergen-specific IgE production and suppression of an established Th2-type response by immunization with DNA encoding hypoallergenic allergen derivatives of Bet v 1, the major birch-pollen allergen. Eur J Immunol 33 (2003) 1667-1676
19. Bauer R., Scheiblhofer S., Kern K., Gruber C., Stepanoska T., Thalhamer T., et al. Generation of hypoallergenic DNA vaccines by forced ubiquitination: preventive and therapeutic effects in a mouse model of allergy. J Allergy Clin Immunol 118 (2006) 269-276
20. Stutz H., Wallner M., Malissa Jr. H., Bordin G., and Rodriguez A.R. Detection of coexisting protein conformations in capillary zone electrophoresis subsequent to transient contact with sodium dodecyl sulfate solutions. Electrophoresis 26 (2005) 1089-1105
21. Sreerama N., Venyaminov S.Y., and Woody R.W. Estimation of protein secondary structure from circular dichroism spectra: inclusion of denatured proteins with native proteins in the analysis. Anal Biochem 287 (2000) 243-251
22. Rajashankar K., Bufe A., Weber W., Eschenburg S., Lindner B., and Betzel C. Structure of the functional domain of the major grass-pollen allergen Phlp 5b. Acta Crystallogr D Biol Crystallogr 58 (2002) 1175-1181
23. Spangfort M.D., Mirza O., Ipsen H., Van Neerven R.J., Gajhede M., and Larsen J.N. Dominating IgE-binding epitope of Bet v 1, the major allergen of birch pollen, characterized by X-ray crystallography and site-directed mutagenesis. J Immunol 171 (2003) 3084-3090
24. Holm J., Gajhede M., Ferreras M., Henriksen A., Ipsen H., Larsen J.N., et al. Allergy vaccine engineering: epitope modulation of recombinant Bet v 1 reduces IgE binding but retains protein folding pattern for induction of protective blocking-antibody responses. J Immunol 173 (2004) 5258-5267
25. Buhot C., Chenal A., Sanson A., Pouvelle-Moratille S., Gelb M.H., Menez A., et al. Alteration of the tertiary structure of the major bee venom allergen Api m 1 by multiple mutations is concomitant with low IgE reactivity. Protein Sci 13 (2004) 2970-2978
26. Ferreira F., Briza P., Infuhr D., Schmidt G., Wallner M., Wopfner N., et al. Modified recombinant allergens for safer immunotherapy. Inflamm Allergy Drug Targets 5 (2006) 5-14
27. Ferreira F., Hirtenlehner K., Jilek A., Godnik-Cvar J., Breiteneder H., Grimm R., et al. Dissection of immunoglobulin E and T lymphocyte reactivity of isoforms of the major birch pollen allergen Bet v 1: potential use of hypoallergenic isoforms for immunotherapy. J Exp Med 183 (1996) 599-609
28. Vrtala S., Hirtenlehner K., Vangelista L., Pastore A., Eichler H.G., Sperr W.R., et al. Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy. J Clin Invest 99 (1997) 1673-1681
29. Takai T., Mori A., Yuuki T., Okudaira H., and Okumura Y. Non-anaphylactic combination of partially deleted fragments of the major house dust mite allergen Der f 2 for allergen-specific immunotherapy. Mol Immunol 36 (1999) 1055-1065
30. Vrtala S., Hirtenlehner K., Susani M., Hufnagl P., Binder B.R., Vangelista L., et al. Genetic engineering of recombinant hypoallergenic oligomers of the major birch pollen allergen, Bet v 1: candidates for specific immunotherapy. Int Arch Allergy Immunol 118 (1999) 218-219
31. King T.P., Jim S.Y., Monsalve R.I., Kagey-Sobotka A., Lichtenstein L.M., and Spangfort M.D. Recombinant allergens with reduced allergenicity but retaining immunogenicity of the natural allergens: hybrids of yellow jacket and paper wasp venom allergen antigen 5s. J Immunol 166 (2001) 6057-6065
32. Linhart B., Jahn-Schmid B., Verdino P., Keller W., Ebner C., Kraft D., et al. Combination vaccines for the treatment of grass pollen allergy consisting of genetically engineered hybrid molecules with increased immunogenicity. FASEB J 16 (2002) 1301-1303
33. Westritschnig K., Linhart B., Focke-Tejkl M., Pavkov T., Keller W., Ball T., et al. A hypoallergenic vaccine obtained by tail-to-head restructuring of timothy grass pollen profilin, Phl p 12, for the treatment of cross-sensitization to profilin. J Immunol 179 (2007) 7624-7634
34. Vrtala S., Focke M., Kopec J., Verdino P., Hartl A., Sperr W.R., et al. Genetic engineering of the major timothy grass pollen allergen, Phl p 6, to reduce allergenic activity and preserve immunogenicity. J Immunol 179 (2007) 1730-1739
35. Westritschnig K., Focke M., Verdino P., Goessler W., Keller W., Twardosz A., et al. Generation of an allergy vaccine by disruption of the three-dimensional structure of the cross-reactive calcium-binding allergen, Phl p 7. J Immunol 172 (2004) 5684-5692
36. Vidard L., Rock K.L., and Benacerraf B. Diversity in MHC class II ovalbumin T cell epitopes generated by distinct proteases. J Immunol 149 (1992) 498-504
37. Carra J.H., Welcher B.C., Schokman R.D., David C.S., and Bavari S. Mutational effects on protein folding stability and antigenicity: the case of streptococcal pyrogenic exotoxin A. Clin Immunol 108 (2003) 60-68
38. Adkinson N.F., Sobotka A.K., and Lichtenstein L.M. Evaluation of the quantity and affinity of human IgG "blocking" antibodies. J Immunol 122 (1979) 965-972
39. Francis J.N., Till S.J., and Durham S.R. Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. J Allergy Clin Immunol 111 (2003) 1255-1261
40. Jutel M., Pichler W.J., Skrbic D., Urwyler A., Dahinden C., and Muller U.R. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-gamma secretion in specific allergen-stimulated T cell cultures. J Immunol 154 (1995) 4187-4194
41. Secrist H., Chelen C.J., Wen Y., Marshall J.D., and Umetsu D.T. Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals. J Exp Med 178 (1993) 2123-2130
42. Rolland J.M., Gardner L.M., and O'Hehir R.E. Allergen-related approaches to immunotherapy. Pharmacol Ther 121 (2009) 273-284
43. Akdis C.A., and Akdis M. Mechanisms and treatment of allergic disease in the big picture of regulatory T cells. J Allergy Clin Immunol 123 (2009) 735-748
44. Weiss R., Hammerl P., Hartl A., Hochreiter R., Leitner W.W., Scheiblhofer S., et al. Design of protective and therapeutic DNA vaccines for the treatment of allergic diseases. Curr Drug Targets Inflamm Allergy 4 (2005) 585-597